×
This post has expired! It was posted more than 90 days ago.
<- Back

152726 - Discontinuing osteoporosis pharmacotherapy in postmenopausal women – can they risk taking a break?

  • : Online

A four-part newsletter series on osteoporosis therapy in post-menopausal women. This Clinical Brief 4-part series will explore the evidence for the importance of long-term therapy in osteoporosis, and the risks of taking a "drug holiday".

Relevance to General Practice

Despite the availability of safe and efficacious PBS-subsidised pharmacotherapy, osteoporosis is significantly under-diagnosed and inadequately managed in Australia. With an ageing population and without improvements in in treatment rates, the incidence of osteoporotic fracture is expected to increase by an estimated 11% over the next 5 years. This 4-part Clinical Brief series explores evidence for the importance of long-term pharmacotherapy in osteoporosis, and the issues that GPs need to be aware of when considering the possibility of a ‘drug holiday’’

Learning outcomes
  • Recall the different modes of action, onset of action and duration of action of osteoporosis pharmacotherapies
  • Counsel patients on the safety and efficacy of long-term osteoporosis pharmacotherapy
  • Evaluate the benefits and risks of long-term osteoporosis pharmacotherapy, including the risk of osteonecrosis of the jaw and atypical fracture of the femur
  • Implement strategies for discontinuation of osteoporosis pharmacotherapies in order to minimise the risk of rebound fracture
  • Delivery
    Title
    152726 - Discontinuing osteoporosis pharmacotherapy in postmenopausal women – can they risk taking a break?
    Location
    Duration
    1 hour
    Start Date
    17-Jun-2019
    End Date
    31-Dec-2019
    CPD Points
    1 hour
    Price
    Free
    Location
    Online
    Contact Phone
    Log in into view this field.
    HealthcareLink